Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference

Ascentage Pharma initiated with a Buy at Rodman & Renshaw

Piper Sandler Reaffirms Their Buy Rating on Ascentage Pharma Group International Unsponsored ADR (AAPG)

Ascentage Pharma Gets FDA's IND Clearance for APG-3288

Hong Kong Stock Movement | ASCENTAGE-B (06855) Rises Nearly 4% as Novel BTK Degrader APG-3288's IND Application Receives US FDA Clearance

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

ASCENTAGE PHARMA GROUP-B (06855): David Sidransky to be Appointed as Lead Independent Non-Executive Director

CICC Maintains "Outperform" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU

ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP

ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances

Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting

HK Stock Movement | ASCENTAGE-B (06855) Rises Over 6% as POLARIS-1 Study for Olverembatinib (Nerlynx®) Gains FDA and EMA Approval

ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL

Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA

Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025

ASCENTAGE PHARMA GROUP-B (06855) Grants 1.3045 Million Restricted Share Units and 736,600 Share Options

Hong Kong Stock: ASCENTAGE-B Rises Over 3%

HK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation